Karyopharm Therapeutics Inc
Veridion Score
Composite trend over time
Why is KPTI moving today?
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KPTI.
KPTI insider activity
Karyopharm Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$369K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 2026-05-14 | Poulton Stuart | Insider | sell | $9.50 | 403 | 94,821 | $4K | SEC Form 4 |
| 2026-05-15 | 2026-05-14 | Rangwala Reshma | Insider | sell | $9.50 | 408 | 56,829 | $4K | SEC Form 4 |
| 2026-05-15 | 2026-05-14 | Cheng Sohanya Roshan | Insider | sell | $9.50 | 324 | 107,940 | $3K | SEC Form 4 |
| 2026-05-15 | 2026-05-14 | Abate Kristin | Insider | sell | $9.50 | 53 | 23,801 | $504 | SEC Form 4 |
| 2026-05-15 | 2026-05-14 | Paulson Richard A. | Insider | sell | $9.50 | 2,203 | 269,747 | $21K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 22 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moKPTI contract awards, year to date.
Public federal awards linked to this ticker.
KPTI lobbying filings, year to date.
Registered lobbying filings matched to Karyopharm Therapeutics Inc.
SIDLEY AUSTIN LLP